The Possible Use of Spleen Cells for the Adoptive Immunotherapy of Cancer Patients

Overview

Journal Surg Today

Specialty General Surgery

Date 1993 Jan 1

PMID 8461601

Authors

M Katano

H Yamamoto

E Kubota

M Nakamura

T Matsuo

F Nagumo

T Hisatsugu

T Katsuki

J Tadano

Affiliations

Soon will be listed here.

Abstract

The possible use of spleen-derived mononuclear cells (SPMC) for the intentional and economical adoptive immunotherapy of cancer patients was studied. SPMC were obtained from spleens resected surgically from patients with gastric cancer or idiopathic thrombocytopenic purpura (ITP). When SPMC were cultured in recombinant interleukin 2 (rIL2), SPMC, in the form of interleukin-activated killer spleen cells (IL-SP) proliferated in six of eight cases. CD8+ lymphocytes were the major expanding cell population in most SPMC cultures and IL-SP showed a significant cytolytic activity against cultured tumor cells during cell proliferation. When cultured with a streptococcal preparation, OK-432, for 24 to 48 h, SPMC showed cytotoxic activity against tumor cells and were expressed as OK-432 activated killer spleen cells (OK-SP). The effects of supernatants from IL-SP and OK-SP on tumor cell growth were also examined. The supernatants from IL-SP and OK-SP significantly inhibited cell growth in 3 and 10 out of 11 cases, respectively, while those from OK-SP showed higher growth inhibitory activity than those from IL-SP. The results of this study indicate the potential of SPMC as effector cells for the adoptive immunotherapy of cancer patients.

References

Rosenberg S . Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today. 1988; 9(2):58-62. DOI: 10.1016/0167-5699(88)91261-3. View

Fisher R, COLTMAN Jr C, Doroshow J, Rayner A, Hawkins M, Mier J . Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med. 1988; 108(4):518-23. DOI: 10.7326/0003-4819-108-4-518. View

Uchida A, Micksche M . Lysis of fresh human tumor cells by autologous large granular lymphocytes from peripheral blood and pleural effusions. Int J Cancer. 1983; 32(1):37-44. DOI: 10.1002/ijc.2910320107. View

De Ley M, Claeys H . Streptococcal preparation OK-432-induced interferon in human leukocytes: purification and characterization. Int Arch Allergy Appl Immunol. 1984; 74(1):21-8. DOI: 10.1159/000233510. View

Toge T, Seto Y, Kuroi K, Yamada H, Aratani K, Fujita T . Relationship of the distribution of Leu-2+ cells with suppressor cell activities in the spleen and lymph-nodes from gastric cancer. Jpn J Surg. 1987; 17(2):72-7. DOI: 10.1007/BF02470644. View

Katano M, Mizoguchi T, Yamamoto H, Nakamura M, Matsuo T, Hisatugu T . The antitumor effects of locally injecting human peripheral blood mononuclear cells treated with OK-432 into the tumor site: the possible role of a tumor growth inhibitory factor (TGIF). Jpn J Surg. 1990; 20(1):76-82. DOI: 10.1007/BF02470717. View

Yanagawa E, Toge T, Sawamura A, Kegoya Y, Baba N, Hattori T . The regulation of natural killer cell activity by splenic nonspecific suppressor cells and its modification in cancer patients. Jpn J Surg. 1988; 18(6):660-7. DOI: 10.1007/BF02471527. View

Heo D, Whiteside T, Johnson J, Chen K, Barnes E, Herberman R . Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. Cancer Res. 1987; 47(23):6353-62. View

Rosenberg S, Spiess P, Lafreniere R . A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986; 233(4770):1318-21. DOI: 10.1126/science.3489291. View

10.

Miller S . Production and renewal of murine natural killer cells in the spleen and bone marrow. J Immunol. 1982; 129(5):2282-6. View

11.

Grimm E, Mazumder A, Zhang H, Rosenberg S . Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982; 155(6):1823-41. PMC: 2186695. DOI: 10.1084/jem.155.6.1823. View

12.

Uchida A, Micksche M . Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432. J Natl Cancer Inst. 1983; 71(4):673-80. View

13.

Rosenberg S, Packard B, Aebersold P, Solomon D, Topalian S, TOY S . Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319(25):1676-80. DOI: 10.1056/NEJM198812223192527. View

14.

Ichimura O, Suzuki S, Saito M, Sugawara Y, Ishida N . Augmentation of interleukin 1 and interleukin 2 production by OK-432. Int J Immunopharmacol. 1985; 7(2):263-70. DOI: 10.1016/0192-0561(85)90035-9. View

15.

Yamamoto A, Nagamuta M, Usami H, Sugawara Y, Watanabe N, Niitsu Y . Release of tumor necrosis factor (TNF) into mouse peritoneal fluids by OK-432, a streptococcal preparation. Immunopharmacology. 1986; 11(2):79-86. DOI: 10.1016/0162-3109(86)90027-5. View

16.

Rosenberg S, Lotze M, Muul L, Chang A, Avis F, Leitman S . A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987; 316(15):889-97. DOI: 10.1056/NEJM198704093161501. View

17.

Akiyoshi T, Koba F, Miyazaki S, Arinaga S, Tsuji H . [NK activity, TCGF production and generation of cell-mediated cytotoxicity in spleen cells from gastric cancer patients]. Nihon Geka Gakkai Zasshi. 1983; 84(9):957-60. View

18.

Damle N, Doyle L, Bradley E . Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol. 1986; 137(9):2814-22. View

19.

Katano M, Yamamoto H, Nakamura M, Matsuo T, Hisatsugu T . Synergistic effects of TGIF and interferon gamma (IFN-gamma) on tumor cell growth. TGIF and IFN-gamma. Biotherapy. 1990; 2(1):33-40. DOI: 10.1007/BF02172074. View

20.

Itoh K, Tilden A, Kumagai K, Balch C . Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells. J Immunol. 1985; 134(2):802-7. View